Proteostasis Therapeutics, Inc. (NASDAQ:PTI)‘s stock had its “outperform” rating reissued by stock analysts at Leerink Swann in a note issued to investors on Wednesday, The Fly reports. They presently have a $9.00 price objective on the stock, down from their prior price objective of $17.00. Leerink Swann’s target price would indicate a potential upside of 301.79% from the stock’s current price.

PTI has been the topic of several other reports. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 30th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Proteostasis Therapeutics in a report on Friday, June 30th.

Proteostasis Therapeutics (NASDAQ:PTI) opened at 2.24 on Wednesday. Proteostasis Therapeutics has a 12 month low of $2.04 and a 12 month high of $20.63. The stock’s 50 day moving average is $3.58 and its 200-day moving average is $7.36. The stock’s market capitalization is $56.23 million.

WARNING: “Leerink Swann Reiterates “Outperform” Rating for Proteostasis Therapeutics, Inc. (PTI)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/16/leerink-swann-reiterates-outperform-rating-for-proteostasis-therapeutics-inc-pti.html.

Several institutional investors have recently modified their holdings of PTI. Candriam Luxembourg S.C.A. raised its position in shares of Proteostasis Therapeutics by 66.7% in the first quarter. Candriam Luxembourg S.C.A. now owns 75,000 shares of the company’s stock valued at $587,000 after buying an additional 30,000 shares in the last quarter. MARSHALL WACE ASIA Ltd bought a new position in shares of Proteostasis Therapeutics during the first quarter valued at approximately $5,946,000. FMR LLC raised its position in shares of Proteostasis Therapeutics by 30.4% in the first quarter. FMR LLC now owns 2,878,804 shares of the company’s stock valued at $22,513,000 after buying an additional 671,936 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Proteostasis Therapeutics by 21.4% in the fourth quarter. Teachers Advisors LLC now owns 12,617 shares of the company’s stock valued at $155,000 after buying an additional 2,223 shares in the last quarter. Finally, TD Asset Management Inc. bought a new position in shares of Proteostasis Therapeutics during the first quarter valued at approximately $199,000. Hedge funds and other institutional investors own 75.40% of the company’s stock.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

The Fly

Receive News & Stock Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related stocks with our FREE daily email newsletter.